MicroRNAs and triple negative breast cancer

Elvira D'Ippolito, Marilena V. Iorio

Research output: Contribution to journalArticlepeer-review


Triple Negative Breast Cancer (TNBC) is a very aggressive tumor subtype, which still lacks specific markers for an effective targeted therapy. Despite the common feature of negativity for the three most relevant receptors (ER, PgR and HER2), TNBC is a very heterogeneous disease where different subgroups can be recognized, and both gene and microRNA profiling studies have recently been carried out to dissect the different molecular entities. Moreover, several microRNAs playing a crucial role in triple negative breast cancer biology have been identified, providing the experimental basis for a possible therapeutic application. Indeed, the causal involvement of microRNAs in breast cancer and the possible use of these small noncoding RNA molecules as biomarkers has been extensively studied with promising results. Their application as therapeutic tools might represent an innovative approach, especially for a tumor subgroup still lacking an efficient and specific therapy such as TNBC. In this review, we summarize our knowledge on the most important microRNAs described in TNBC.

Original languageEnglish
Pages (from-to)22202-22220
Number of pages19
JournalInternational Journal of Molecular Sciences
Issue number11
Publication statusPublished - Nov 11 2013


  • Breast cancer
  • MicroRNA
  • Triple negative

ASJC Scopus subject areas

  • Computer Science Applications
  • Molecular Biology
  • Catalysis
  • Inorganic Chemistry
  • Spectroscopy
  • Organic Chemistry
  • Physical and Theoretical Chemistry


Dive into the research topics of 'MicroRNAs and triple negative breast cancer'. Together they form a unique fingerprint.

Cite this